Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CAI:PHAR's 5-Year Yield-on-Cost % is ranked worse than 66.73% of 511
companies
in the Drug Manufacturers industry
Industry Median: 2.3
vs CAI:PHAR: 1.34
Egyptian International Pharmaceutical Investments (CAI:PHAR) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Egyptian International Pharmaceutical Investments 5-Year Yield-on-Cost % Related Terms
CAI:PHAR vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
Egyptian International Pharmaceutical Investments 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a 5-Year Yield-on-Cost % of 1.34 as of Aug. 15, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Egyptian International Pharmaceutical Investments and its competitors. This is 48% below median its historical median of 2.58. Over the past decade, Egyptian International Pharmaceutical Investments' 5-Year Yield-on-Cost % has ranged from 1.24 to 5.80. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #341 out of 511 companies in the Drug Manufacturers industry, placing it in the top 66.7%.
Is Egyptian International Pharmaceutical Investments' 5-Year Yield-on-Cost % too high?
Egyptian International Pharmaceutical Investments' current 5-Year Yield-on-Cost % of 1.34 is 48% below median its 10-year median of 2.58. Over the past 10 years, this metric has ranged from a low of 1.24 to a high of 5.80. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.30. Egyptian International Pharmaceutical Investments' value of 1.34 is 41.7% below this industry median. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #341 out of 511 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #341 out of 511 companies for 5-Year Yield-on-Cost %. This places Egyptian International Pharmaceutical Investments in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.30. Egyptian International Pharmaceutical Investments' value of 1.34 is 41.7% below this benchmark. Historically, Egyptian International Pharmaceutical Investments' own 5-Year Yield-on-Cost % has ranged from 1.24 to 5.80 over the past decade. While the company's 10-year median is 2.58 vs. the industry median of 2.30, Egyptian International Pharmaceutical Investments has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.30, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egyptian International Pharmaceutical Investments's current 5-Year Yield-on-Cost % of 1.34 is 41.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current 5-Year Yield-on-Cost % is 1.34, which is 48% below median its own 10-year median of 2.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£60.08, compared to a current price of E£143.00 — trading 138% above its estimated fair value. The current 5-Year Yield-on-Cost % is 1.34, which is 48% below median its 10-year median of 2.58 and 41.7% below the Drug Manufacturers industry median of 2.30. Egyptian International Pharmaceutical Investments' overall GF Score™ is 61/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current 5-Year Yield-on-Cost % is 1.34 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£143.00 is trading 138% above its estimated GF Value™ of E£60.08.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
5-Year Yield-on-Cost %: 1.34 (48% below median its 10-year median of 2.58)
GF Value™: E£60.08 vs. price of E£143.00 (138% above fair value)
Industry Position: 41.7% below the Drug Manufacturers median (#341 of 511)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
61GF Score
Get the complete analysis for CAI:PHAR
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
